Pneumococcal disease is a leading killer of both children and adults worldwide. It is caused by a common bacterium, the Streptococcus pneumoniae or pneumococcus. Infection can result in pneumonia and infections of the brain and blood. An estimated 1.6 million people die annually from the disease, including up to 1 million children under five years of age.
The most effective way to prevent pneumococcal disease is through vaccination. Vaccines provide immunity against some of the 90+ strains (or serotypes) of pneumococcus. PCV13-valent vaccine protects against 13 of them.
The Bobo-PREP project (Bobo Pneumococcal Research and Evaluation Program) aims to evaluate the impact of PCV13 vaccine in the Bobo-Dioulasso area of Burkina Faso. Epidemiological data, collected by AMP and Centre Muraz from 2002 to 2009, will be used to assess PCV13 impact on meningitis effect and carrier nasopharyngeal prevalence of vaccine and non-vaccine serotypes of pneumoccocus among immunization-age children, other children, and non-immunized adults.
This evaluation will be combined to:
- A retrospective study to estimate PCV13 impact on children under five hospitalized with pneumonia
- An investigation on meningitis and pneumonia after-effects
- An economical and anthropological study to estimate the cost of the disease and the value of this vaccine for the population
The Bobo-PREP project is implemented for three years (2014-2017) with funding from Gavi, the Vaccine Alliance.